Patent intelligence · US
US 7727970
Multiple promoter expression cassettes for simultaneous delivery of RNAi agents targeted to Hepatitis C virus
Multiple promoter expression cassettes for simultaneous delivery of RNAi agents targeted to Hepatitis C virus
Patent details — US 7727970
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 1, 2010
- Expiration
- May 27, 2030
- Applicant
- Benitec, Inc.
- Claims
- 2
- CPC classes
- A61K, A61K38/00, A61P, A61P1/16
Quick answer
US 7727970 (Multiple promoter expression cassettes for simultaneous delivery of RNAi agents targeted to Hepatitis C virus) is held by Benitec, Inc.. Status: granted. Granted Jun 1, 2010. Expires May 27, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Benitec, Inc.
- Grant date
- Expiration
- Claims
- 2
- CPC classes
- A61K, A61K38/00, A61P, A61P1/16, A61P31/12, A61P31/14
More from Benitec, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11932852
Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof
granted -
US 11535851
Reagents for treatment of hepatitis B virus (HBV) infection and use thereof
granted -
US 11234994
Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof
granted -
US 11142765
Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof
granted -
US 10898505
Reagents for treatment of hepatitis B virus (HBV) infection and use thereof
granted -
US 10000753
Age-related macular degeneration treatment
granted -
US 9518260
Pain treatment
granted -
US 9410154
HBV treatment
granted
Frequently asked questions
What is US patent 7727970?
US 7727970 (Multiple promoter expression cassettes for simultaneous delivery of RNAi agents targeted to Hepatitis C virus) is held by Benitec, Inc.. Status: granted. Granted Jun 1, 2010. Expires May 27, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7727970?
Benitec, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 13 pharmaceutical patents for this assignee.
When does US 7727970 expire?
Our index shows an expiration date of May 27, 2030 (4 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.